2VSA Stock Overview
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Verastem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.10 |
| 52 Week High | US$13.73 |
| 52 Week Low | US$3.36 |
| Beta | 0.53 |
| 1 Month Change | 8.60% |
| 3 Month Change | 6.88% |
| 1 Year Change | 184.35% |
| 3 Year Change | -64.40% |
| 5 Year Change | -55.89% |
| Change since IPO | -89.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VSA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.9% | -4.9% | -1.5% |
| 1Y | 184.3% | -19.9% | 0.9% |
Return vs Industry: 2VSA exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 2VSA exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 2VSA volatility | |
|---|---|
| 2VSA Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2VSA has not had significant price volatility in the past 3 months.
Volatility Over Time: 2VSA's weekly volatility has decreased from 148% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 73 | Dan Paterson | www.verastem.com |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
Verastem, Inc. Fundamentals Summary
| 2VSA fundamental statistics | |
|---|---|
| Market cap | €257.61m |
| Earnings (TTM) | -€82.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs 2VSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$87.37m |
| Earnings | -US$87.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 56.4% |
How did 2VSA perform over the long term?
See historical performance and comparison